Trevena (TRVN) Downgraded by Zacks Investment Research to Hold
According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
A number of other research analysts have also issued reports on the stock. ValuEngine lowered shares of Trevena from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. HC Wainwright reiterated a “hold” rating and issued a $1.25 target price on shares of Trevena in a research note on Thursday, March 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $4.69.
Trevena (NASDAQ:TRVN) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. As a group, analysts anticipate that Trevena will post -0.37 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of TRVN. ExodusPoint Capital Management LP bought a new stake in shares of Trevena in the 1st quarter valued at approximately $46,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Trevena in the 1st quarter valued at approximately $50,000. Renaissance Technologies LLC lifted its stake in shares of Trevena by 84.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,284,038 shares of the biopharmaceutical company’s stock valued at $2,003,000 after purchasing an additional 587,100 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Trevena by 15.2% in the 1st quarter. Northern Trust Corp now owns 156,298 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 20,592 shares during the last quarter. Finally, Alpine Global Management LLC bought a new stake in shares of Trevena in the 1st quarter valued at approximately $31,000. 21.54% of the stock is owned by hedge funds and other institutional investors.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: What is Blockchain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.